- Home
- CRNX
as 07-26-2024 4:00pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.2B | IPO Year: | 2018 |
| Target Price: | $65.33 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.76 - $55.78 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,974,000 | Revenue Growth: | -53.93% |
| Revenue Growth (this year): | -46.87% | Revenue Growth (next year): | 576.22% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Knight Jeff E. | CRNX | Chief Operating Officer | Jul 15 '24 | Sell | $55.00 | 27,000 | $1,485,000.00 | 51,653 | SEC Form 4 |
| Hassard James | CRNX | Chief Commercial Officer | Jul 5 '24 | Sell | $44.08 | 15,000 | $661,200.00 | 29,259 | SEC Form 4 |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Jul 3 '24 | Sell | $44.87 | 14,375 | $645,006.25 | 28,507 | SEC Form 4 |
| Wilson Marc | CRNX | CFO | Jun 28 '24 | Sell | $43.61 | 32,129 | $1,401,145.69 | 111,092 | SEC Form 4 |
| Knight Jeff E. | CRNX | Chief Operating Officer | Jun 26 '24 | Sell | $44.38 | 956 | $42,427.28 | 52,580 | SEC Form 4 |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Jun 25 '24 | Sell | $45.37 | 3,000 | $136,110.00 | 80,643 | SEC Form 4 |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Jun 24 '24 | Sell | $45.73 | 9,500 | $434,435.00 | 27,786 | SEC Form 4 |
| Hassard James | CRNX | Chief Commercial Officer | Jun 21 '24 | Sell | $44.66 | 15,000 | $669,900.00 | 29,259 | SEC Form 4 |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Jun 10 '24 | Sell | $43.86 | 3,000 | $131,580.00 | 83,643 | SEC Form 4 |
| Betz Stephen F. | CRNX | Chief Scientific Officer | May 28 '24 | Sell | $47.49 | 3,000 | $142,470.00 | 86,643 | SEC Form 4 |
| Betz Stephen F. | CRNX | Chief Scientific Officer | May 10 '24 | Sell | $49.43 | 3,000 | $148,290.00 | 89,643 | SEC Form 4 |
| Struthers Richard Scott | CRNX | President & CEO | May 8 '24 | Sell | $49.40 | 107,448 | $5,307,931.20 | 257,485 | SEC Form 4 |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Apr 15 '24 | Sell | $44.47 | 14,375 | $639,256.25 | 27,786 | SEC Form 4 |
| Struthers Richard Scott | CRNX | President & CEO | Apr 4 '24 | Sell | $49.17 | 40,951 | $2,013,560.67 | 237,835 | SEC Form 4 |
| Okey Stephanie | CRNX | Director | Mar 28 '24 | Sell | $46.38 | 17,500 | $811,650.00 | 6,000 | SEC Form 4 |
| Knight Jeff E. | CRNX | Chief Operating Officer | Mar 22 '24 | Sell | $44.22 | 30,000 | $1,326,600.00 | 54,939 | SEC Form 4 |
| Knight Jeff E. | CRNX | Chief Operating Officer | Mar 22 '24 | Sell | $45.39 | 2,359 | $107,075.01 | 52,580 | SEC Form 4 |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Mar 20 '24 | Sell | $45.89 | 4,375 | $200,768.75 | 28,500 | SEC Form 4 |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Mar 20 '24 | Sell | $43.28 | 10,000 | $432,800.00 | 28,500 | SEC Form 4 |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Mar 20 '24 | Sell | $43.69 | 714 | $31,194.66 | 27,786 | SEC Form 4 |
| Fust Matthew K | CRNX | Director | Mar 20 '24 | Sell | $43.57 | 12,500 | $544,625.00 | 18,536 | SEC Form 4 |
| Fust Matthew K | CRNX | Director | Mar 20 '24 | Sell | $43.57 | 12,500 | $544,625.00 | 18,536 | SEC Form 4 |
| Fust Matthew K | CRNX | Director | Mar 20 '24 | Sell | $43.58 | 17,500 | $762,650.00 | 18,536 | SEC Form 4 |
| Fust Matthew K | CRNX | Director | Mar 20 '24 | Sell | $45.50 | 17,500 | $796,250.00 | 18,536 | SEC Form 4 |
| Wilson Marc | CRNX | CFO | Mar 18 '24 | Sell | $42.91 | 6,942 | $297,881.22 | 110,630 | SEC Form 4 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
MT Newswires
9 days ago
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,485,000, According to a Recent SEC Filing
GuruFocus.com
14 days ago
Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
GlobeNewswire
16 days ago
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
17 days ago
JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating
GuruFocus.com
a month ago
Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
MT Newswires
a month ago
Crinetics Pharmaceuticals Insider Sold Shares Worth $434,435, According to a Recent SEC Filing
GlobeNewswire
a month ago
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.